Aetna modified CPB 0521 for prostate cancer screening, effective November 27, 2025. Here's what changes for your billing team.
Aetna updated its prostate cancer screening coverage policy under CPB 0521. The update codifies medical necessity criteria for PSA testing (CPT 84153, 84152, 84154 and HCPCS G0103) and digital rectal examination (HCPCS G0102), while explicitly excluding a growing list of newer biomarker and genetic tests from coverage. If your practice or lab bills any of the nine "not covered" CPT codes — including 0021U, 0133U, 0433U, 0495U, and 81539 — this policy directly affects your reimbursement.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Prostate Cancer Screening |
| Policy Code | CPB 0521 |
| Change Type | Modified |
| Effective Date | November 27, 2025 |
| Impact Level | High — multiple non-covered codes with active billing exposure |
| Specialties Affected | Urology, Primary Care, Lab/Pathology, Medical Oncology, Genetic Counseling |
| Key Action | Audit your charge capture for excluded biomarker codes before billing any Aetna prostate cancer screening claims after November 27, 2025 |
Aetna Prostate Cancer Screening Coverage Criteria and Medical Necessity Requirements 2025
The Aetna prostate cancer screening coverage policy draws clear lines around what counts as medical necessity and what doesn't. Understand these criteria before you bill.
Standard PSA screening (CPT 84153 for total PSA, CPT 84152 for complexed PSA, CPT 84154 for free PSA, or HCPCS G0103) is covered for average-risk men starting at age 45. High-risk men — specifically African-American men and men with a family history of prostate cancer — qualify at age 40.
Age 75 is the hard stop for routine screening. Aetna will not cover routine prostate cancer screening for members 75 or older unless their life expectancy is 10 years or greater. Document life expectancy clearly in the record if you're billing routine screening for this age group.
Annual PSA screening is covered when a patient has a previously elevated PSA or signs and symptoms of prostate disease. This is a diagnostic indication, not preventive — use ICD-10 R97.20 or R97.21 for elevated PSA, or the appropriate N40.x code for enlarged prostate. The distinction matters for reimbursement, especially on plans that exclude preventive benefits.
Diagnostic PSA testing for men with signs or symptoms of prostate cancer, and for follow-up of confirmed prostate cancer patients, is covered regardless of age or preventive benefit status. This is one of the cleaner parts of the policy — diagnostic PSA testing (CPT 84153) doesn't depend on preventive benefit inclusion.
Digital rectal examination (HCPCS G0102) is covered annually as a service. Pair it with Z12.5 for screening encounters or the appropriate clinical ICD-10 for diagnostic encounters.
Prior authorization requirements are not explicitly called out in this policy, but coverage is tightly tied to patient age, risk category, and indication. A claim denial is most likely when your documentation doesn't match the eligibility criteria above. Verify benefit plan descriptions for plans that exclude preventive services — diagnostic PSA coverage holds regardless, but preventive screening coverage does not.
Aetna Prostate Cancer Screening Exclusions and Non-Covered Indications
This is where the billing exposure lives. Aetna excludes a long list of newer biomarker and genetic screening tests from coverage under CPB 0521. These are classified as experimental, investigational, or unproven.
The core logic: none of these tests have demonstrated proven value for prostate cancer screening. That word matters. Some of these markers may be ordered in diagnostic workups elsewhere, but under this coverage policy, Aetna won't pay for them as screening tools.
Biomarker and genetic tests explicitly excluded:
| # | Excluded Procedure |
|---|---|
| 1 | Stockholm3 — covered nowhere under this policy |
| 2 | Four-kallikrein panel (total PSA, free PSA, intact PSA, hK2) — billed as CPT 81539, not covered |
| 3 | PCA3 (Prostate cancer gene 3) — billed as CPT 81313, not covered |
| 4 | EpiSwitch Prostate Screening Test — no covered indication |
| 5 | TMPRSS2:ERG gene fusion — not covered |
| 6 | BRAF mutations — CPT 81210, not covered under this policy |
| 7 | Apifiny non-PSA blood test (Armune BioScience) — CPT 0021U, not covered |
| 8 | RNAinsight for ProstateNext / ProstateNext — CPT 0133U, not covered |
| 9 | EpiSwitch / 5 DNA regulatory markers — CPT 0433U, not covered |
| 10 | Circulating plasma protein panel (tPSA, fPSA, KLK2, PSP94, GDF15) — CPT 0495U, not covered |
| 11 | Selenium measurement in blood or tissue — CPT 84255, not covered |
| 12 | Immunoassay for other analytes (including interleukin-6, NGAL, endoglin, TGF-β1) — CPT 83520, not covered |
This is a pattern Aetna has used before in genetic and molecular testing policies. The payer is signaling that clinical evidence hasn't caught up to the commercial availability of these tests. Until the evidence base shifts, billing any of these against an Aetna prostate screening claim will result in a claim denial.
If your ordering physicians are using these tests, flag it now with your compliance officer. The financial exposure on repeated claims for non-covered codes can add up fast.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| PSA screening, average-risk men age 45+ | Covered | CPT 84153, 84152, 84154; HCPCS G0103; ICD-10 Z12.5 | Check plan for preventive benefit inclusion |
| PSA screening, high-risk men age 40+ (African-American or family history) | Covered | CPT 84153, 84152, 84154; HCPCS G0103; ICD-10 Z80.42, Z15.03 | Document risk factor clearly |
| Routine PSA screening, members 75+ | Not Covered (unless life expectancy ≥10 years) | CPT 84153; ICD-10 Z12.5 | Document life expectancy if billing this group |
| Annual PSA screening with previously elevated PSA | Covered | CPT 84153; ICD-10 R97.20, R97.21 | Diagnostic, not preventive — use correct ICD-10 |
| PSA with signs/symptoms of prostate cancer | Covered | CPT 84153, 84152, 84154; ICD-10 N40.x, N42.3x | Covered regardless of preventive benefit status |
| PSA follow-up for confirmed prostate cancer | Covered | CPT 84153; ICD-10 C61, Z85.46 | Diagnostic coverage — no age restriction |
| Annual digital rectal examination | Covered | HCPCS G0102; ICD-10 Z12.5 | Annual frequency limit applies |
| Four-kallikrein panel (CPT 81539) | Experimental | CPT 81539 | Not covered for screening indication |
| PCA3 testing (CPT 81313) | Experimental | CPT 81313 | Not covered under this policy |
| Stockholm3 | Experimental | No specific CPT listed | No covered indication |
| BRAF mutation analysis (CPT 81210) | Experimental | CPT 81210 | Not covered under CPB 0521 |
| Selenium measurement (CPT 84255) | Experimental | CPT 84255 | No proven value for this indication |
| Apifiny test (CPT 0021U) | Experimental | CPT 0021U | No covered indication |
| RNAinsight/ProstateNext (CPT 0133U) | Experimental | CPT 0133U | Not covered |
| 5 DNA regulatory markers (CPT 0433U) | Experimental | CPT 0433U | Not covered |
| Circulating plasma protein panel (CPT 0495U) | Experimental | CPT 0495U | Not covered |
| Immunoassay for prostate biomarkers (CPT 83520) | Experimental | CPT 83520 | Includes IL-6, NGAL, endoglin, TGF-β1 |
Aetna Prostate Cancer Screening Billing Guidelines and Action Items 2025
These are the steps your billing team should take now, before November 27, 2025 is live on your next claim submission.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for all non-covered codes. Pull claims from the last 90 days for CPT codes 0021U, 0133U, 0433U, 0495U, 81210, 81313, 81539, 83520, and 84255 billed to Aetna. If any of those hit, understand whether they were for prostate screening indications — those will deny under the updated CPB 0521 policy. |
| 2 | Update your ICD-10 mapping for PSA claims. Don't use Z12.5 (screening) when the clinical indication is elevated PSA (R97.20 or R97.21) or signs and symptoms. The distinction matters for plans that exclude preventive services. Diagnostic PSA claims survive a preventive benefit exclusion — a misapplied Z12.5 does not. |
| 3 | Flag charts for patients age 75 and older. If your providers routinely order PSA for this age group, build a documentation checkpoint. The claim needs evidence of life expectancy ≥10 years to support medical necessity. Without that in the record, expect a denial. |
| 4 | Verify high-risk patient documentation at the time of order. For men age 40–44 receiving PSA screening, the chart must reflect the high-risk category — African-American race or family history of prostate cancer. ICD-10 codes Z80.42 (family history) and Z15.03 (genetic susceptibility) support this. Don't wait until the claim is denied to find the documentation gap. |
| 5 | Communicate with ordering physicians about excluded biomarker tests. If your urologists or primary care providers are ordering Stockholm3, four-kallikrein panels, or PCA3 tests for Aetna patients, they need to know those won't be covered under CPB 0521. As a general billing best practice — not a requirement stated in CPB 0521 — consider issuing advance notice to patients when out-of-pocket exposure is possible. Loop in your compliance officer if you have high volume of these orders. |
| 6 | Check benefit plans individually for preventive service exclusions. Aetna notes that some plans exclude preventive services entirely. Diagnostic PSA testing holds up regardless, but preventive-coded claims do not. Build a pre-claim verification step for Aetna members where PSA is ordered as routine screening. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Prostate Cancer Screening Under CPB 0521
Covered CPT and HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 84152 | CPT | Prostate specific antigen (PSA); complexed (direct measurement) |
| 84153 | CPT | Prostate specific antigen (PSA); total |
| 84154 | CPT | Prostate specific antigen (PSA); free |
| G0102 | HCPCS | Prostate cancer screening; digital rectal examination |
| G0103 | HCPCS | Prostate cancer screening; prostate specific antigen test (PSA) |
Not Covered / Experimental CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0021U | CPT | Oncology (prostate), detection of 8 autoantibodies (ARF 6, NKX3-1, 5'-UTR-BMI1, CEP 164, 3'-UTR-Ropp...) | Not covered for indications listed in CPB 0521 |
| 0133U | CPT | Hereditary prostate cancer–related disorders, targeted mRNA sequence analysis panel (11 genes)... | Not covered for indications listed in CPB 0521 |
| 0433U | CPT | Oncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm... | Not covered for indications listed in CPB 0521 |
| 0495U | CPT | Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15)... | Not covered for indications listed in CPB 0521 |
| 81210 | CPT | BRAF (B-Raf proto-oncogene, serine/threonine kinase) gene analysis, V600 | Not covered for indications listed in CPB 0521 |
| 81313 | CPT | PCA3/KLK3 (prostate cancer antigen 3/kallikrein-related peptidase 3)... | Not covered for indications listed in CPB 0521 |
| 81539 | CPT | Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA...) | Not covered for indications listed in CPB 0521 |
| 83520 | CPT | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative | Not covered for indications listed in CPB 0521 |
| 84255 | CPT | Chemistry, Selenium | Not covered for indications listed in CPB 0521 |
Key ICD-10-CM Diagnosis Codes
The descriptions below for N40.0–N40.3 and N42.30–N42.39 reflect the language used in CPB 0521. More granular descriptions (e.g., "with lower urinary tract symptoms," "prostatic intraepithelial neoplasia I") come from the ICD-10-CM code book and are not part of the policy source.
| Code | Description (per CPB 0521) |
|---|---|
| C61 | Malignant neoplasm of prostate |
| D07.5 | Carcinoma in situ of prostate |
| D29.1 | Benign neoplasm of prostate |
| D40.0 | Neoplasm of uncertain behavior of prostate |
| N40.0 | Enlarged prostate |
| N40.1 | Enlarged prostate |
| N40.2 | Enlarged prostate |
| N40.3 | Enlarged prostate |
| N42.30 | Dysplasia of prostate |
| N42.31 | Dysplasia of prostate |
| N42.32 | Dysplasia of prostate |
| N42.33 | Dysplasia of prostate |
| N42.34 | Dysplasia of prostate |
| N42.35 | Dysplasia of prostate |
| N42.36 | Dysplasia of prostate |
| N42.37 | Dysplasia of prostate |
| N42.38 | Dysplasia of prostate |
| N42.39 | Dysplasia of prostate |
| R97.20 | Elevated prostate specific antigen [PSA] |
| R97.21 | Elevated prostate specific antigen [PSA] |
| Z12.5 | Encounter for screening for malignant neoplasm of prostate |
| Z15.03 | Genetic susceptibility to malignant neoplasm of prostate |
| Z80.42 | Family history of malignant neoplasm of prostate |
| Z85.46 | Personal history of malignant neoplasm of prostate |
Get the Full Picture for CPT 84153
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.